MSACL 

The Metabolomic Landscape of Chemotherapy Resistance
Mon 11:00 AM - Track 2: Therapeutic Metabolomics
Anders Nordstrom
Karolinska Institute, Sweden
View Long Abstract
Acquired or inherent cellular resistance to cytotoxic drugs is a major problem in the treatment of cancer patients. We are using a leukemic cancer cell line system and mass spectrometry based metabolomics to probe (1) how the metabolome evolves as a cancer cell line progress from being sensitive to being resistant towards cytotoxic agents and (2) identify differences in the metabolome between an isolated sub-clone of inherently resistant leukemic cancer cells and the metabolome of the entire cancer cell culture. Alterations in parts of pyrimidine-, propanoate- and CoA-metabolism was associated with emergence of resistance to a particular cytotoxic agent.
Email: [email protected]